[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555524":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":11,"studyPopulation":11,"armGroups":28,"interventions":39,"overallOfficials":11,"centralContacts":49,"locations":58,"responsibleParty":77,"collaborators":79,"id":83,"slug":11,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":11,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":11,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"University of Maryland St. Joseph Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Ketorolac results in decreased post-op opioid use when administered in the first 48 hours (measured by calculating the total amount of MME utilized during the patient's inpatient stay and comparing the control and experimental groups).",null,"12 months",[14,16],{"measure":15,"description":11,"timeFrame":12},"Ketorolac use does not decrease spinal fusion rates in one or two level fusion (failure defined as by > than 2 degrees motion on standardized flexion\u002Fextension x-rays compared to pre-op imaging analyzed by SpineCAMP software at 6 and 12 months post-op).",{"measure":17,"description":11,"timeFrame":12},"Ketorolac use decreases average length of hospital stay (length of stay for both the control group and the experimental group will be counted, and a statistical average for each group will be calculated and compared).",{"allocation":19,"interventionModel":20,"interventionModelDescription":11,"primaryPurpose":21,"observationalModel":11,"timePerspective":11,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":11,"whoMasked":24},"TRIPLE",[25,26,27],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[29,34],{"label":30,"type":31,"description":11,"interventionNames":32},"Ketorolac arm","ACTIVE_COMPARATOR",[33],"Drug: Ketorolac Tromethamine",{"label":35,"type":36,"description":11,"interventionNames":37},"Placebo Arm","PLACEBO_COMPARATOR",[38],"Drug: Placebo",[40,45],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"DRUG","Ketorolac Tromethamine","IV Ketorolac 15mg every 6 hours, x 4 doses",[30],{"type":41,"name":46,"description":47,"armGroupLabels":48,"otherNames":11},"Placebo","IV saline as placebo",[35],[50,55],{"name":51,"role":52,"phone":53,"phoneExt":11,"email":54},"Aja Janyavula","CONTACT","410-427-5459","ajanyavula@umm.edu",{"name":56,"role":52,"phone":53,"phoneExt":11,"email":57},"Sam Rudow","samuel.rudow@umm.edu",[59],{"facility":5,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Towson","Maryland","21204","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-76.60191,39.4015,{"lat":70,"lon":69},[73,74],{"name":56,"role":52,"phone":53,"phoneExt":11,"email":57},{"name":75,"role":76,"phone":11,"phoneExt":11,"email":11},"Justin Tortolani, MD","PRINCIPAL_INVESTIGATOR",{"type":78,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[80],{"name":81,"class":82},"Medical Metrics Diagnostics, Inc","INDUSTRY","100555524",false,"NCT06513208","Ketorolac Effects on Post-operative Pain and Lumbar Fusion","Ketorolac Effects on Post-operative Pain and Lumbar Fusion: a Double Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-85 years old (inclusive)\n* Elective posterior lumbar instrumented fusion\n* One or two level fusion\n* Consent to participate in study and willing to adhere to study follow up\n* English proficiency\n\nExclusion Criteria:\n\n* \\\u003C 18 or \\> 85 years old\n* History of renal failure, dialysis, or creatinine over 1.50 mg\u002Fdl\n* Active or recent smoker (active within past 6 months)\n* Revision surgery\n* Auto\u002Fworker compensation\n* Active cancer or history of chemotherapy in past 6 months\n* Active narcotic use within 3 months of surgery date\n* Infection at operative levels\n* Any allergies to NSAIDs or Opioids",true,"ALL","18 Years","85 Years",{"count":94,"type":95},140,"ESTIMATED","INTERVENTIONAL",[98],"PHASE4","A double blind prospective randomized trial of IV ketorolac vs. placebo in management of patients undergoing lumbar one or two level spinal fusions.",[101],"Lumbar Spinal Fusion",[103,104,105],"ketorolac","toradol","lumbar spine fusion","2025-12-18",{"date":108,"type":109},"2025-12-22","ACTUAL",{"date":111,"type":95},"2026-01",{"date":113,"type":95},"2027-06",{"name":5,"class":6},1]